Menu
Back to Journals » Clinical Interventions in Aging » Volume 4
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
Authors Rackoff P
Published 5 May 2009 Volume 2009:4 Pages 207—213
DOI https://doi.org/10.2147/CIA.S4080
Review by Single anonymous peer review
Peer reviewer comments 3
Paula Rackoff
Division of Rheumatology, Beth Israel Medical Center, New York, NY, USA
Abstract: Fragility fractures that occur as a result of osteoporosis are frequently associated with chronic pain and decreased quality of life as well as significant morbidity and mortality. Fracture reduction, however, is often less than optimal due to poor compliance with medications. Studies have demonstrated that risedronate, a heterocyclic nitrogen containing bisphosphonate can reduce vertebral, nonvertebral, and hip fracture incidence in postmenopausal women, in men, and in subsets of older patients at great risk of falls and fragility. The mechanism, efficacy, dosing options, and tolerability of risedronate are reviewed.
Keywords: osteoporosis, fracture
© 2009 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.